{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T16:58:15Z","timestamp":1795107495742,"version":"4.10.3"},"reference-count":42,"publisher":"BMJ","issue":"2","funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Thorax"],"published-print":{"date-parts":[[2018,2]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Little is known about the prevalence of severe, uncontrolled eosinophilic asthma (SUEA) and associated costs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aims<\/jats:title><jats:p>We sought to determine the prevalence of SUEA and compare asthma-related healthcare resource use (HCRU) and associated costs with overall means for a general asthma population.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This cohort study evaluated anonymised medical record data (December 1989 through June 2015) from the Clinical Practice Research Datalink and the Optimum Patient Care Research Database to study UK patients with active asthma (diagnostic code and one or more drug prescriptions in the baseline year), aged 5 years and older, without concomitant COPD, and with recorded eosinophil count. SUEA was defined as two or more asthma attacks during 1 baseline year preceding a high blood eosinophil count (\u22650.3\u00d710<jats:sup>9<\/jats:sup>\/L) for patients prescribed long-acting \u03b2<jats:sub>2<\/jats:sub>-agonist (LABA) and high-dosage inhaled corticosteroids (ICS) during baseline plus 1 follow-up year. We compared asthma-related HCRU and associated direct costs (2015 pounds sterling, \u00a3) during the follow-up year for SUEA versus the general asthma population.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 363 558 patients with active asthma and recorded eosinophil count, 64% were women, mean (SD) age was 49 (21) years; 43% had high eosinophil counts, 7% had two or more attacks in the baseline year and 10% were prescribed high-dosage ICS\/LABA for 2 study years. Overall, 2940 (0.81%; 95%\u2009CI 0.78% to 0.84%) patients had SUEA. Total mean per-patient HCRU and associated costs were four times greater for SUEA versus all patients (HCRU and cost ratios 3.9; 95%\u2009CI 3.7 to 4.1).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Less than 1% of patients in a general asthma population had SUEA. These patients accounted for substantially greater asthma-related HCRU and costs than average patients with asthma.<\/jats:p><\/jats:sec>","DOI":"10.1136\/thoraxjnl-2017-210531","type":"journal-article","created":{"date-parts":[[2017,9,17]],"date-time":"2017-09-17T00:25:29Z","timestamp":1505607929000},"page":"116-124","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":144,"title":["Healthcare resource use and costs of severe, uncontrolled eosinophilic asthma in the UK general population"],"prefix":"10.1136","volume":"73","author":[{"given":"Marjan","family":"Kerkhof","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trung N","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan B","family":"Soriano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarowar","family":"Golam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth V","family":"Hillyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9728-9992","authenticated-orcid":false,"given":"David B","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2017,9,16]]},"reference":[{"key":"2020050723430852000_73.2.116.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31678-6"},{"key":"2020050723430852000_73.2.116.2","unstructured":"Global Initiative for Asthma (GINA). GINA Report, Global Strategy for Asthma Management and Prevention. http:\/\/ginasthma.org\/ (accessed 11 Jul 2017)."},{"key":"2020050723430852000_73.2.116.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.08.042"},{"key":"2020050723430852000_73.2.116.4","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jaip.2015.08.003","article-title":"Utilization and costs of severe\u00a0uncontrolled asthma in a managed-care setting","volume":"4","author":"Zeiger","year":"2016","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2020050723430852000_73.2.116.5","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2013-204114"},{"key":"2020050723430852000_73.2.116.6","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2466-9-24"},{"key":"2020050723430852000_73.2.116.7","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2010.137414"},{"key":"2020050723430852000_73.2.116.8","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00202013"},{"key":"2020050723430852000_73.2.116.9","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2014-205634"},{"key":"2020050723430852000_73.2.116.10","doi-asserted-by":"publisher","DOI":"10.1111\/cea.12345"},{"key":"2020050723430852000_73.2.116.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2014.04.011"},{"key":"2020050723430852000_73.2.116.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2014.06.005"},{"key":"2020050723430852000_73.2.116.13","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(15)00367-7"},{"key":"2020050723430852000_73.2.116.14","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1164\/rccm.201602-0419OC","article-title":"Inflammatory and comorbid features of patients with severe asthma and frequent exacerbations","volume":"195","author":"Denlinger","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2020050723430852000_73.2.116.15","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.jaip.2016.11.007","article-title":"Identifying risk of future asthma attacks using UK medical record data: a respiratory effectiveness group initiative","volume":"5","author":"Blakey","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2020050723430852000_73.2.116.16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60988-X"},{"key":"2020050723430852000_73.2.116.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1403290"},{"key":"2020050723430852000_73.2.116.18","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(15)00042-9"},{"key":"2020050723430852000_73.2.116.19","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2015-207630"},{"key":"2020050723430852000_73.2.116.20","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"key":"2020050723430852000_73.2.116.21","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u03b22-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"key":"2020050723430852000_73.2.116.22","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2006.061572"},{"key":"2020050723430852000_73.2.116.23","unstructured":"Clinical Practice Research Datalink. http:\/\/www.cprd.com\/home\/ (accessed 11 Jul 2017)."},{"key":"2020050723430852000_73.2.116.24","unstructured":"Boston Collaborative Drug Surveillance Program. The Clinical Practice Research Datalink. http:\/\/www.bu.edu\/bcdsp\/gprd\/ (accessed 11 Jul 2017).http:\/\/optimumpatientcare.org\/opcrd\/ (accessed 11 Jul 2017)."},{"key":"2020050723430852000_73.2.116.25","unstructured":"Optimum Patient Care Research Database (OPCRD). http:\/\/optimumpatientcare.org\/database-overview\/ (accessed 8 Sep 2017)"},{"key":"2020050723430852000_73.2.116.26","unstructured":"UK National Health Service. Hospital Episode Statistics (HES). http:\/\/content.digital.nhs.uk\/hes (accessed 11 Jul 2017)."},{"issue":"Suppl 2","key":"2020050723430852000_73.2.116.27","doi-asserted-by":"crossref","first-page":"S99","DOI":"10.1513\/AnnalsATS.201309-300RM","article-title":"Quality standards for real-world research. Focus on observational database studies of comparative effectiveness","volume":"11","author":"Roche","year":"2014","journal-title":"Ann Am Thorac Soc"},{"key":"2020050723430852000_73.2.116.28","unstructured":"UK National Health Service. Quality and Outcomes Framework (QOF). http:\/\/www.hscic.gov.uk\/qof (accessed 11 Jul 2017)."},{"key":"2020050723430852000_73.2.116.29","unstructured":"British Thoracic Society, Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma.\u00a0A national clinical guideline. 2014 https:\/\/www.brit-thoracic.org.uk\/document-library\/clinical-information\/asthma\/btssign-asthma-guideline-2014\/ (accessed 11 Jul 2017)."},{"key":"2020050723430852000_73.2.116.30","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200801-060ST"},{"key":"2020050723430852000_73.2.116.31","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2014-206069"},{"key":"2020050723430852000_73.2.116.32","unstructured":"Enhancing the QUAlity and Transparency Of health Research (EQUATOR) Network. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. https:\/\/www.equator-network.org\/reporting-guidelines\/cheers\/ (accessed 11 Jul 2017)."},{"key":"2020050723430852000_73.2.116.33","doi-asserted-by":"crossref","unstructured":"Husereau D , Drummond M , Petrou S , et al . Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. BMJ 2013;346:f1049.doi:10.1136\/bmj.f1049","DOI":"10.1136\/bmj.f1049"},{"key":"2020050723430852000_73.2.116.34","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.313.7052.275"},{"key":"2020050723430852000_73.2.116.35","doi-asserted-by":"crossref","first-page":"14081","DOI":"10.1038\/npjpcrm.2014.81","article-title":"Cost-effectiveness of initiating extrafine- or standard size-particle inhaled corticosteroid for asthma in two health-care systems: a retrospective matched cohort study","volume":"24","author":"Martin","year":"2014","journal-title":"NPJ Prim Care Respir Med"},{"key":"2020050723430852000_73.2.116.36","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jaip.2016.07.015","article-title":"Blood eosinophil count and outcomes in severe uncontrolled asthma: a prospective study","volume":"5","author":"Zeiger","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2020050723430852000_73.2.116.37","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jaip.2015.10.002","article-title":"Characteristics and outcomes of HEDIS-defined asthma patients with COPD diagnostic coding","volume":"4","author":"Zeiger","year":"2016","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2020050723430852000_73.2.116.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2015.04.010"},{"key":"2020050723430852000_73.2.116.39","doi-asserted-by":"publisher","DOI":"10.1136\/thorax.57.10.880"},{"key":"2020050723430852000_73.2.116.40","unstructured":"NHS National Services Scotland, Information Services Division. Health conditions general practice: Asthma. http:\/\/www.isdscotland.org\/Health-Topics\/General-Practice\/GP-consultations\/Health-Conditions\/Asthma\/index.asp (accessed 29 Jul 2017)."},{"key":"2020050723430852000_73.2.116.41","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyh299"},{"key":"2020050723430852000_73.2.116.42","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2015-207530"}],"container-title":["Thorax"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/thoraxjnl-2017-210531","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T06:01:48Z","timestamp":1601100108000},"score":1,"resource":{"primary":{"URL":"https:\/\/thorax.bmj.com\/lookup\/doi\/10.1136\/thoraxjnl-2017-210531"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,16]]},"references-count":42,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2018,1,15]]},"published-print":{"date-parts":[[2018,2]]}},"alternative-id":["10.1136\/thoraxjnl-2017-210531"],"URL":"https:\/\/doi.org\/10.1136\/thoraxjnl-2017-210531","relation":{},"ISSN":["0040-6376","1468-3296"],"issn-type":[{"value":"0040-6376","type":"print"},{"value":"1468-3296","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,16]]}}}